From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
Lilly's Chief Scientific Officer has big plans for the next generation of weight loss drugs
Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic ...
Lilly's Chief Scientific Officer: 'We have an obligation to go after big problems'
Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic ...
Eli Lilly wants to use its weight loss drug windfall to fight Alzheimer's and hearing loss
The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the ...
Eli Lilly aims to invest in 'big problems hiding in plain sight' using obesity windfall
Eli Lilly wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in ...
Eli Lilly Shifts Focus from GLP-1 Success to Neurological Breakthroughs
Eli Lilly (LLY, Financial) is set to pivot its focus beyond obesity after a monumental windfall from its GLP-1 drugs. At its ...
Next generation weight loss drugs aim to save muscle
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
NBC DFW2d
From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs
Eli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy. The development of pills and more ...